BCR signaling pathway was associated with survival and development of DLBCL cells, and we determined several BCR signaling components, including PI3K (47.1%), AKT2 (41.2%), JAK2 (42.7%), STAT3 (50.0%), MAPK (48.5%), BCL10 (60.3%), and NF-κB p50 (58.8%). The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.